Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)
Open Access
- 8 February 2021
- Vol. 11 (2), e040210
- https://doi.org/10.1136/bmjopen-2020-040210
Abstract
Introduction: The optimal treatment for extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae bloodstream infections has yet to be defined. Retrospective studies have shown conflicting results, with most data suggesting the non-inferiority of beta-lactam–beta-lactamase inhibitor combinations compared with carbapenems. However, the recently published MERINO trial failed to demonstrate the non-inferiority of piperacillin–tazobactam to meropenem. The potential implications of the MERINO trial are profound, as widespread adoption of carbapenem treatment will have detrimental effects on antimicrobial stewardship in areas endemic for ESBL and carbapenem-resistant bacteria. Therefore, we believe that it is justified to re-examine the comparison in a second randomised controlled trial prior to changing clinical practice.Methods and analysis: PeterPen is a multicentre, investigator-initiated, open-label, randomised controlled non-inferiority trial, comparing piperacillin–tazobactam with meropenem for third-generation cephalosporin-resistant Escherichia coli and Klebsiella bloodstream infections. The study is currently being conducted in six centres in Israel and one in Canada with other centres from Israel, Italy and Canada expected to join. The two primary outcomes are all-cause mortality at day 30 from enrolment and treatment failure at day seven (death, fever above 38°C in the last 48 hours, continuous symptoms, increasing Sequential Organ Failure Assessment Score or persistent blood cultures with the index pathogen). A sample size of 1084 patients was calculated for the mortality endpoint assuming a 12.5% mortality rate in the control group with a 5% non-inferiority margin and assuming 100% follow-up for this outcome.Ethics and dissemination: The study is approved by local and national ethics committees as required. Results will be published, and trial data will be made available.Trial registration numbers: ClinicalTrials.gov Registry (NCT03671967); Israeli Ministry of Health Trials Registry (MOH_2018-12-25_004857).Funding Information
- European Society of Clinical Microbiology and Infectious Diseases (Research Grant programme 2020)
This publication has 38 references indexed in Scilit:
- Power failure: why small sample size undermines the reliability of neuroscienceNature Reviews Neuroscience, 2013
- Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial InfectionsAntimicrobial Agents and Chemotherapy, 2012
- -Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective CohortsClinical Infectious Diseases, 2011
- Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for SepsisAntimicrobial Agents and Chemotherapy, 2010
- Therapeutic drug monitoring of β-lactams in critically ill patients: proof of conceptInternational Journal of Antimicrobial Agents, 2010
- Killing of Escherichia coli by β-lactams at different inoculaDiagnostic Microbiology and Infectious Disease, 2009
- Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteriaIntensive Care Medicine, 2006
- Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum -LactamasesClinical Infectious Diseases, 2004
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996
- Repeated assessment of results in clinical trials of cancer treatmentThe British Journal of Radiology, 1971